

1 **Full title: *In vivo reprogramming of murine host immune response***
2 ***genes following Leishmania major infection.***

3

4 Short title: Host transcriptomic changes following *Leishmania major*
5 infection

6

7 Gopinath Venugopal^{1¶}, Jordan T. Bird^{2,3,¶}, Charity L. Washam^{2,3}, Hayden Roys¹, Anne
8 Bowlin¹, Stephanie D. Byrum^{2,3,*}, and Tiffany Weinkopff^{1,*}

9

10 ¹*Department of Microbiology and Immunology, College of Medicine, University of*
11 *Arkansas for Medical Sciences, Little Rock, AR, USA 72205*

12 ²*Department of Biochemistry and Molecular Biology, College of Medicine, University*
13 *of Arkansas for Medical Sciences, Little Rock, AR, USA 72205*

14 ³*Arkansas Children's Research Institute, Little Rock, AR, USA 72202*

15

16 * Corresponding author

17 Email: TWeinkopff@uams.edu, SBYRUM@uams.edu

18

19 ¶These authors contributed equally to this work.

20

21

22 **Abstract**

23 *Leishmania* parasites cause cutaneous leishmaniasis (CL), a pathologic disease
24 characterized by disfiguring, ulcerative skin lesions. Both parasite and host gene
25 expression following infection with various *Leishmania* species has been investigated
26 in vitro, but global transcriptional analysis following *L. major* infection in vivo is lacking.
27 Thus, we conducted a comprehensive transcriptomic profiling study combining bulk
28 RNA sequencing (RNA-Seq) and single-cell RNA sequencing (scRNA-Seq) to identify
29 global changes in gene expression in vivo following *L. major* infection. Bulk RNA-Seq
30 analysis revealed that host immune response pathways like the antigen processing
31 and presentation pathway were significantly enriched amongst differentially expressed
32 genes (DEGs) upon infection, while ribosomal pathways were significantly
33 downregulated in infected mice compared to naive controls. scRNA-Seq analyses
34 revealed cellular heterogeneity including distinct resident and recruited cell types in
35 the skin following murine *L. major* infection. Within the individual immune cell types,
36 several DEGs indicative of many interferon induced GTPases and antigen
37 presentation molecules were significantly enhanced in the infected ears including
38 macrophages (*Gbp2*, *H2-K1*, *H2-Aa*, *H2-Ab1*), resident macrophages (*H2-K1*, *H2-D1*,
39 *Gbp4*, *Gbp8*, *Gbp2*), and inflammatory monocytes (*Gbp2*, *Gbp5*, *Gbp7*, *Gbp3*).
40 Ingenuity Pathway Analysis of scRNA-Seq data indicated the antigen presentation
41 pathway was increased with infection, while EIF2 signaling is the top downregulated
42 pathway followed by eIF4/p70S6k and mTOR signaling in multiple cell types including
43 macrophages, BECs, and LECs. Altogether, this transcriptomic profile highlights
44 known recruitment of myeloid cells to lesions and recognizes a previously undefined
45 role for EIF2 signaling in murine *L. major* infection in vivo.

46 **Author summary**

47 *Leishmania major* cause cutaneous leishmaniasis, which is characterized by
48 disfiguring, ulcerative skin lesions. Here, we show murine *L. major*-directed
49 reprogramming of the host transcriptome in vivo. Our bulk RNA-Seq analyses revealed
50 upregulation of antigen processing and presentation pathway, while the host ribosomal
51 pathway was downregulated following *L. major* infection. Similarly, scRNA-Seq
52 analyses revealed the upregulation of transcripts responsible for antigen presentation
53 and host defense proteins like guanylate binding proteins (GBPs) alongside the
54 downregulation of EIF2 signalling at the site of *L. major* infection. Overall, our
55 transcriptomic dataset not only provides the comprehensive list of gene expression at
56 the single-cell resolution, and highlights a previously undefined role for EIF2 signalling
57 during murine *L. major* infection in vivo.

58

59

60 Introduction

61 Leishmaniasis is a multifaceted disease caused by different species of obligate
62 intracellular protozoan parasites of the genus *Leishmania*, belonging to the
63 Trypanosomatid family. Depending on the complex interaction between the species
64 and the host immune system, the disease can vary in severity resulting in a wide
65 spectrum of clinical outcomes that have been classified into the following categories:
66 cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), or diffuse CL
67 (DCL) where symptoms remain localized to skin or mucosal surfaces, and a life-
68 threatening condition called visceral leishmaniasis (VL) where parasites migrate to the
69 internal organs like the liver, spleen and bone marrow(1). As per the World Health
70 Organization (WHO), leishmaniasis is still considered to be major public health
71 problem due to its annual incidence up to 1.7 million new cases worldwide(1,2).
72 *Leishmania* spp. possess a variety of virulence mechanisms, which helps parasites to
73 survive and replicate inside the parasitophorous vacuoles of macrophages, and
74 elimination of parasites by macrophages is critical for host resistance(3). Although,
75 macrophages are the primary host cell for *Leishmania* parasites, recruited
76 neutrophils(4–6) and dendritic cells(7–9) at the site of infection can also harbor
77 parasites, suggesting that these immune cells could play an important role in host-
78 parasite interplay. *Leishmania* parasites use several strategies to evade the host
79 immune response for its intracellular survival including modulating the host immune
80 response by altering T cell responses, impeding antigen display by MHCII, hindering
81 nitric oxide production(10,11). Importantly, *Leishmania* parasites can escape from
82 oxidative burst and they fail to activate optimal macrophage innate immune
83 responses(12,13). However, changes at the transcriptional level following *Leishmania*

84 infection within different cell types and especially within the hostile tissue
85 microenvironment is still largely unknown.

86 Of the species belonging to subgenus *Leishmania*, *L. major* is an important
87 etiological agent of cutaneous leishmaniasis (CL) and possesses clinical and
88 epidemiological importance, especially in parts of Asia, the Middle East, Northern
89 Africa, and Southern Europe(14). Although CL is not fatal and considered to be a self-
90 healing disease, the development of nodules or papules followed by ulcerations at the
91 site of promastigote infection is the hallmark of the disease; importantly, both parasite
92 replication and the host immune response can contribute to the disease pathology(14).
93 CL produces permanently disfiguring skin lesions that are associated with massive
94 immune cell recruitment, across the blood vascular endothelium, and into the skin
95 where the parasite resides(15–19). While CD4⁺ Th1 cells producing IFN γ are required
96 to activate macrophages to kill parasites, the exacerbated activation and sustained
97 recruitment of immune cells including neutrophils, NK cells, Ly6C⁺ inflammatory
98 monocytes, and CD4⁺ and CD8⁺ T lymphocytes induces a chronic inflammatory
99 response; this chronic inflammation leads to tissue necrosis and skin damage, a
100 feature of non-healing lesions(20–22).

101 The *L. major* genome was completed in 2005(23). Until recently, many studies
102 examining the host response relied mostly on microarray-based or serial analysis of
103 gene expression tag approaches. Using these approaches, previous studies
104 compared the host gene expression profile between infection with promastigotes and
105 amastigotes or different species of *Leishmania*(24–30). Transcriptomic studies
106 dramatically enhanced our understanding of CL. In general, these studies concluded
107 that human or murine macrophages infected by various *Leishmania* species
108 downregulate pro-inflammatory gene expression, while concomitantly upregulating the

109 expression of anti-inflammatory genes(31,32). However, microarray-based
110 approaches have technical limitations such as hybridization and cross hybridization
111 artefacts, dye-based detection issues, certain probes cannot be included on the
112 microarrays, and the inability to detect 5' and 3' UTRs boundaries(33,34). In recent
113 years, RNA-Seq has emerged as a powerful tool to study transcriptional changes in
114 many disease conditions due to its high sensitivity. Moreover, transcriptomic profiling
115 using RNA-Seq following infection with various species of *Leishmania* has been mostly
116 applied to in vitro experiments and some studies have investigated transcriptional
117 changes in the human or murine host as well as the parasite simultaneously(35–42).
118 A recent study comparing the gene expression profile of primary cutaneous lesions
119 from *L. braziliensis*-infected patients with or without pentavalent antimony treatment
120 revealed most of the differentially expressed transcripts were correlated with
121 components of cytotoxicity related pathways and parasite load in the skin(39). While
122 another study using RNA-Seq from the same group revealed a consistent and
123 significant myeloid interferon stimulated gene (ISG) signature in skin lesions from *L.*
124 *braziliensis*-infected patients(43). Altogether, these studies revealed that the host
125 immune response upregulates transcripts related to both pro-inflammatory and anti-
126 inflammatory responses during leishmaniasis(44,45). Furthermore, none of the RNA-
127 Seq studies to date have characterized the global transcriptional reprogramming
128 following *L. major* infection in vivo, which is the most widely used murine model of CL
129 to study disease pathogenesis and parasite-host interactions. The *Leishmania* field
130 also lacks a comprehensive murine transcriptomic profile that applies more recent
131 genomic technologies like scRNA-Seq to identify transcriptomic changes within
132 individual cell types in vivo. Therefore, the purpose of this study was to generate
133 comprehensive transcriptomic profile using a combination of bulk RNA-Seq and

134 scRNA-Seq to identify global changes in gene expression that occur during murine *L.*
135 *major* infection in vivo.

136 Our bulk RNA-Seq transcriptomic analyses revealed the antigen presentation
137 pathway was significantly upregulated while ribosomal pathways were significantly
138 downregulated by the host following *L. major* infection. Our scRNA-Seq analyses
139 revealed a cellular heterogeneity including distinct resident and recruited cell types at
140 the site of *L. major* infection. Confirming the bulk RNA-Seq, we found macrophages,
141 blood endothelial cells (BECs), and lymphatic endothelial cells (LECs) display a
142 transcriptomic profile associated with increased antigen presentation and decreased
143 EIF2, eIF4/p70S6K, and mTOR signalling suggesting cells in lesions are undergoing
144 a stress response while they participate in Th1 protective immunity. Overall, this study
145 combines bulk RNA-Seq and scRNA-Seq to assemble a comprehensive dataset that
146 defines how the murine host response reprograms individual cell types following *L.*
147 *major* infection to combat the infection.

148

149 **Results**

150 **Mouse model of *L. major* infection**

151 To characterize the transcriptomic landscape during *L. major* infection in vivo, we
152 employed next-generation genome sequencing on RNA analysis with ears from mice
153 that were infected with *L. major* promastigotes and uninfected naive control ears.
154 During this experimental murine model of *L. major* infection, lesion volume peaks
155 between 4-6 weeks post-infection (p.i.) and then the lesion resolves spontaneously,
156 and parasites are present in lesions at this time point (Fig 1A-B). As a result, the host

157 transcriptome was investigated from ear samples collected from experimentally-
158 infected mice at 4 weeks p.i. and compared to naive controls.

159 **Enriched pathways for differentially expressed genes** 160 **during *L. major* infection by bulk RNA-Seq**

161 To compare the gene expression profiles of infected and naive mice, bulk RNA-Seq
162 was performed on *L. major*-infected ears and naive control ears. Transcriptional
163 analysis revealed that ears from infected mice and naive controls were distinct from
164 one another, as determined by multidimensional scaling (MDS) plot and DEG analysis.
165 MDS plot shows the positions of each sample, with samples from different
166 experimental groups being well separated, and samples from the same experimental
167 group clustering together (Fig 1C). Therefore, the distance between samples reveals
168 the distinct pattern of gene expression between the infected and naive animals (Fig
169 1C). To investigate transcriptomic signatures associated with infection, we carried out
170 DEG analysis between infected mice and naive controls by comparing the RNA-Seq
171 read counts of the various genes and subsequently applying the cut-off criteria. High
172 and low expression genes ($\log\text{CPM} > 1$) were included in the volcano plot showing
173 transcriptional differences observed between infected and naive ears (Fig 1D). The
174 gene expression profiles derived from the RNA-Seq data were calculated using the
175 RPKM method and a fold change > 2 and $p < 0.05$ were considered statistically
176 significant. Of more than 10,800 genes that were detectable in the infected ears, we
177 observed that 211 genes were upregulated and 34 genes were downregulated, while
178 10,014 genes did not show any significant differences between naive and *L. major*-
179 infected ears (Fig 1D).

180 Gene set enrichment analysis (GSEA) using KEGG pathways revealed a total
181 of 276 enriched pathways which includes pathways involved in both disease
182 conditions and molecular signaling networks. Specifically, the antigen processing and
183 presentation pathway was found to be significantly enriched amongst DEGs, while the
184 ribosomal pathway was significantly downregulated during *L. major* infection (Fig 1E-
185 F). In addition to antigen processing and presentation, we observed many other host
186 immune response pathways upregulated with infection including: cytokine-cytokine
187 receptor interaction, phagosome, chemokine signaling, cell-adhesion molecules
188 pathway, NK cell mediated cytotoxicity, leukocyte trans-endothelial migration and Fcγ
189 receptor-mediated phagocytosis (Fig 1E). Conversely, top 20 downregulated
190 pathways enriched for DEGs in *L. major* infection were related to ribosomal translation,
191 mineral absorption, ECM-receptor interaction, biosynthesis of unsaturated fatty acids,
192 and steroid biosynthesis (Fig 1F). The top 10 KEGG pathways for both upregulated
193 and downregulated pathways with the fold change and adjusted '*p*' value are listed in
194 Table 1. A number of disease-specific KEGG pathways appeared prominent in the
195 enrichment analysis including *Staphylococcus aureus* infection, autoimmune thyroid
196 disease, and graft vs. host disease (Table S1). Importantly, leishmaniasis emerged as
197 one of the top disease pathways highlighting the quality of the input data for the
198 analysis (Table S1).

199

200

201 **Table 1.** List of top 10 KEGG pathways enriched for differentially expressed genes
 202 (DEGs) following *L. major* infection.

Pathway regulation	KEGG enriched pathways	Avg. log-fold change	Adj. p value
Up regulated	Intestinal immune network for IgA production	5.23228	5.08E-07
	Cytokine-cytokine receptor interaction	8.337469	6.97E-06
	Osteoclast differentiation	7.623207	3.31E-05
	Antigen processing and presentation	4.468822	4.21E-05
	Phagosome	6.527853	0.000106
	Chemokine signaling pathway	8.329182	0.000328
	Hematopoietic cell lineage	6.848572	0.000381
	NOD-like receptor signaling pathway	6.638004	0.000744
	Cell adhesion molecules	6.486765	0.000769
	Natural killer cell mediated cytotoxicity	8.022157	0.002282
Down-regulated	Ribosome	-0.696061	0.004705
	Phototransduction	-0.907101	0.007031
	Mineral absorption	-0.992836	0.015538
	ECM-receptor interaction	-0.889139	0.031673
	Oxytocin signaling pathway	-0.948893	0.031673
	Biosynthesis of unsaturated fatty acids	-1.474018	0.042932
	Estrogen signaling pathway	-1.199847	0.055815
	Steroid biosynthesis	-0.908215	0.058351
	Gastric acid secretion	-0.907101	0.072276
	Fatty acid elongation	-0.892548	0.072946

203

204

205 **Differential gene expression in immune-related pathways** 206 **during *L. major* infection by bulk RNA-Seq**

207 Using hierarchical clustering analysis, we found that a large number of genes were
208 robustly induced in the infected ears compared to the naives (Fig 2A-D). A heat map
209 of the DEGs shows the expression profiles of infected and naive mice resulted in
210 separate clusters (Fig 2). Hierarchical clustering reveals the host immune response to
211 *L. major* infection is closely linked with DEGs from the antigen processing and
212 presentation pathway (*Cd4*, *H2-Q6*, *H2-M3*, *H2-Q4*, *Ifng*, *Cd8b1*, *H2-T22*, *Rfx5*, *Tap1*,
213 *H2-Q7*), chemokine signaling (*Cxcl9*, *Ccl5*, *Ccr7*, *Cxcl10*, *Cxcl5*, *Cxcl16*, *Cxcl1*, *Fgr*,
214 *Pik3cd*), and cell adhesion molecules (*Cd4*, *Itgam*, *Itgal*, *Ctla4*, *Icos* *Itga6*, *Cd274*,
215 *Cd28*, *Cd86*, *Selplg*, *Vcam1*) (Fig 2A-C). Additionally, other immune network pathways
216 enriched for DEGs included cytokine-cytokine receptor interaction, phagosome, toll-
217 like receptor signaling, and leukocyte trans-endothelial migration pathway (Fig S1A-
218 D). In contrast, the biological processes downregulated with infection include
219 ribosomal biogenesis (*Rpl3*, *Rpl37*, *Rps5*, *Rpl11*, *Rplp1*, *Rpl28*, *Rpl19*, *Rps28*, *Rps14*)
220 (Fig 2D). Of note, infected mice clustered together for antigen processing and
221 presentation, chemokine signaling, and the cell adhesion molecules pathways (Fig 2A-
222 C), but one mouse in each group clustered with the opposing experimental group for
223 the ribosomal pathway (Fig 2D). Overall, these results demonstrate the host
224 transcriptome undergoes reprogramming in the skin during *L. major* infection.

225

226

227 **scRNA-Seq reveals the cellular heterogeneity and altered**
228 **transcriptomic profile of individual cell types during murine**
229 ***L. major* infection in vivo**

230 The bulk RNA-Seq analysis revealed global changes in the transcriptional profile
231 between infected mice and naive controls following *L. major* inoculation. To further
232 investigate transcriptomic changes within individual cell types present in leishmanial
233 lesions, scRNA-Seq was performed to provide a deeper understanding of how
234 individual cells function in the tissue microenvironment. Single cells from the ears of
235 infected and naive mice were bar-coded and sequenced using the droplet-based 10X
236 Genomics Chromium platform (Fig 3A). After quality control assessment and filtering,
237 the datasets were processed using Cell Ranger software. Unbiased hierarchical
238 clustering using Seurat provides single-cell transcriptional profiling with 26,558 cells
239 and displayed the cellular heterogeneity which includes both resident and recruited
240 cell types. Cell populations from 35 distinct cell types were defined using canonical
241 markers from published literature and online databases (Fig 3B)(46). The dot plot
242 representing the cell type-specific canonical markers for each cell lineage used to
243 distinguish the 35 distinct clusters is provided (Fig 4A). Amongst the 35 cell types, we
244 identified 16 cell types containing immune cells. Feature plots show the expression of
245 cell type-specific canonical markers (in addition to the cell type-specific canonical
246 markers in Fig 4A) for 12 clusters with corresponding cell types (Fig 4B). Additionally,
247 a heatmap shows the canonical cell type markers from all the immune cell types along
248 with blood endothelial cells (BECs) and lymphatic endothelial cells (LECs) (Fig S2).

249

250

251 **Detection of *Leishmania major* transcripts in multiple cell** 252 **types other than macrophages**

253 Additionally, we aligned the reads to *Leishmania major* (LM) reference genome to
254 detect the presence of *Leishmania* transcripts in 35 different cell type clusters.
255 Interestingly, the differential expression of LM transcripts from scRNA-Seq revealed
256 20 of 35 cell types have at least one LM transcript within that cell. As predicted, we
257 found macrophages are the top immune cell type expressing LM transcripts with about
258 10% of cells containing LM transcripts (Fig 5A-B). We found at least 2% of cells contain
259 LM transcripts in other immune cell types such as resident macrophages, DCs, and
260 neutrophils. At least 1% of the cells in CD4⁺ Th cells, CD8⁺ cytotoxic T cells, T
261 regulatory cells, and basophils also possessed detectable LM transcripts (Fig 5A-B).
262 Consistent with previous findings, we found fibroblasts and keratinocytes also harbor
263 LM transcripts(47). Surprisingly, we also detected LM transcripts in >5% myoblasts
264 but not myocytes and almost 1% of the BECs. Overall, our data shows that multiple
265 other cell types at the infection site harbors LM transcripts suggesting other cell types
266 maybe infected with parasites alongside macrophages, which is the well-established
267 primary host cell for *Leishmania* parasites.

268

269 **scRNA-Seq confirms the immune cell recruitment at the site** 270 **of *L. major* infection in vivo**

271 Murine *L. major* infection leads to the recruitment of immune cells such as
272 inflammatory monocytes, neutrophils, and macrophages to the site of infection.
273 Particularly macrophages play roles in housing the parasite as the replicative niche for
274 the pathogen, as well as a role in parasite control by killing the pathogen. BECs

275 mediate immune cell recruitment to the infected and inflamed tissue and LECs
276 promote immune cell migration away from the infected skin. Therefore, we speculate
277 that immune cells and ECs participate in parasite control and/or immunopathology
278 during CL. As a result, the remainder of the study focuses on 7 immune cell types
279 along with the BEC and LEC clusters. Our UMAP projection displays 13,034 cells in
280 naive ears and 13,524 cells in the infected ears (Fig 6A). Consistent with previous
281 findings in CL, the UMAP plot confirms a significant recruitment of various immune cell
282 types such as inflammatory monocytes, neutrophils, macrophages, dendritic cells, NK
283 cells, and CD4⁺ and CD8⁺ T cells in the infected ears that are seen at higher
284 frequencies compared to naive controls (Fig 6A). Concordant with our scRNA-Seq
285 results, flow cytometric analysis detected a significant increase in the frequency and
286 cell number of macrophages (Fig 6B-C), Ly6C⁺ inflammatory monocytes (Fig 6D-E)
287 and neutrophils (Fig 6F-G) in infected ears compared to naive controls, while no
288 significant alterations in the BEC or LEC populations were observed (Fig 6H-J).
289 Altogether, these data confirm the enhanced immune cell migration during *L. major*
290 infection and transcriptional changes within these individual cell types were
291 investigated.

292

293 **Differential gene expression of immune cell types during *L.*** 294 ***major* infection**

295 To explore the transcriptional changes in a cell type-specific manner, the DEGs were
296 compared between infected and naive mice within an individual cell type following *L.*
297 *major* infection. A volcano plot showing DEGs for macrophages, resident
298 macrophages, inflammatory monocytes, and neutrophils reveals several markers

299 indicative of an increase in myeloid cells in leishmanial lesions (Fig 7A-D). For
300 instance, transcripts commonly elevated within the top 10 DEGs in myeloid cells and
301 dendritic cells (DCs) include *B2m*, *H2-K1*, *Gbp2*, *ligp1*, whereas multiple ribosomal
302 proteins were significantly downregulated within the top 10 DEGs among myeloid cells
303 and DCs (Table 2, 3, and Fig S3). We found consistent elevation of various interferon-
304 induced GTPases like guanylate binding protein (GBP) transcripts with *L. major*
305 infection in macrophages (*Gbp2*) (Table 2A), resident macrophages (*Gbp4*, *Gbp8*,
306 *Gbp2*) (Table 2B), inflammatory monocytes (*Gbp2*, *Gbp5*, *Gbp7*, *Gbp3*) (Table 3A),
307 and DCs (*Gbp2*) (Fig S3). Many of the transcriptomic differences detected in myeloid
308 cells, such as elevated GBPs, were also found in EC populations. For instance, BECs
309 expressed increased *Gbp4* and *Gbp2*, and LECs expressed increased *Gbp4*, *Gbp2*,
310 and *Gbp7* upon infection (Table 4A-B). Furthermore, we detected a significant
311 elevation of both MHCI and MHCII molecules in the infected ears in myeloid cells and
312 ECs, which include *H2-K1*, *H2-Aa*, *H2-Ab1* in macrophages; *H2-K1*, *H2-D1* in resident
313 macrophages; *H2-K1* in DCs, *H2-K1*, *H2-Aa*, *H2-Ab1* in BECs; and *H2-K1*, *H2-D1*,
314 *H2-Q7*, *H2-Aa*, *H2-Ab1* in LECs (Table 2, 4, and Fig S3). In contrast to myeloid cells,
315 DCs, and ECs, we only detected few transcripts that are significantly elevated with
316 infection in T cells including *B2m*, *Satb1*, *Gm42418*, *Gimap6* in CD4⁺ T cells and
317 *Gm42418* in CD8⁺ T cells (Fig S4).

318

319 **Table 2. List of top 10 DEGs enriched in macrophages and resident**
 320 **macrophages following *L. major* infection.**

321 **A**

Macrophages

Gene name	Avg. log-fold change	Adj. p value
<u>Upregulated</u>		
<i>H2-K1</i>	1.203478	2.59E-30
<i>Gm42418</i>	1.013645	3.48E-30
<i>B2m</i>	0.798061	3.33E-28
<i>AW112010</i>	2.205139	1.15E-26
<i>Fth1</i>	1.136905	2.54E-26
<i>Cxcl16</i>	1.778107	5.99E-22
<i>Gbp2</i>	1.141379	1.24E-21
<i>H2-Aa</i>	1.205499	1.62E-20
<i>H2-Ab1</i>	1.264542	9.46E-20
<i>Mmp14</i>	1.784564	6.05E-19
<u>Down regulated</u>		
<i>Rpl32</i>	-1.2065	3.25E-34
<i>Rpl13</i>	-1.23205	2.53E-33
<i>Lyz2</i>	-1.48379	5.03E-32
<i>Rpl18</i>	-1.22252	4.01E-30
<i>S100a4</i>	-1.6294	6.25E-30
<i>Rps18</i>	-1.21541	1.51E-28
<i>Rps14</i>	-1.0183	1.73E-24
<i>Fau</i>	-1.03269	6.54E-23
<i>Ifitm3</i>	-1.30983	8.25E-23
<i>Tpt1</i>	-0.83138	1.52E-22

321 **B**

Resident macrophages

Gene name	Avg. log-fold change	Adj. p value
<u>Upregulated</u>		
<i>H2-K1</i>	1.441768	6.11E-103
<i>B2m</i>	0.935358	1.97E-81
<i>H2-D1</i>	0.761557	4.47E-53
<i>Stat1</i>	1.637833	1.41E-50
<i>Gbp4</i>	1.457725	1.05E-45
<i>Gbp8</i>	1.043486	2.40E-41
<i>Gbp2</i>	1.43904	3.27E-41
<i>Ly6a</i>	1.716371	2.56E-40
<i>AW112010</i>	1.583531	2.66E-38
<i>ligp1</i>	1.437197	1.31E-37
<u>Down regulated</u>		
<i>Pf4</i>	-0.93903	7.66E-51
<i>Cd36</i>	-0.8449	1.88E-25
<i>Rpl12</i>	-0.64508	1.92E-25
<i>S100a6</i>	-0.59164	2.65E-24
<i>Rps25</i>	-0.64782	2.88E-24
<i>Rpl10</i>	-0.71332	3.09E-23
<i>Rnf213</i>	0.85734	3.50E-23
<i>Rps12</i>	-0.5271	3.76E-23
<i>Rpl30</i>	-0.60024	4.48E-23
<i>Rps18</i>	-0.56378	9.59E-21

338

339 **Table 3. List of top 10 DEGs enriched in inflammatory monocytes and**
 340 **neutrophils clusters following *L. major* infection.**

341 **A** Inflammatory monocytes

Gene name	Avg. log-fold change	Adj. p value
Upregulated		
<i>Gm42418</i>	0.849004	1.16E-28
<i>Gbp2</i>	2.686188	1.14E-11
<i>Gbp5</i>	2.139579	6.38E-11
<i>Samhd1</i>	1.180168	8.55E-09
<i>Cxcl10</i>	3.062718	2.43E-08
<i>Gbp7</i>	1.761721	1.11E-07
<i>Cxcl9</i>	3.440467	1.79E-07
<i>Gbp3</i>	1.661975	1.62E-06
<i>liqp1</i>	1.855148	6.54E-06
<i>Nampt</i>	1.57251	1.08E-05
Down regulated		
<i>Fau</i>	-0.67651	8.03E-07
<i>Rpl13</i>	-0.73173	1.00E-06
<i>Rps25</i>	-0.69169	1.18E-06
<i>Lyz2</i>	-0.79057	7.16E-06
<i>Rpl32</i>	-0.66904	1.75E-05
<i>S100a4</i>	-0.85018	0.000375
<i>Tpt1</i>	-0.47099	0.0008
<i>Tmsb4x</i>	-0.51238	0.00088
<i>Rpl9</i>	-0.66084	0.000907
<i>Rpl39</i>	-0.55282	0.001096

341 **B** Neutrophils

Gene name	Avg. log-fold change	Adj. p value
Upregulated		
<i>B2m</i>	1.75856	3.13E-07
<i>Gm42418</i>	0.654377	0.000454
Down regulated		
<i>Sycp2</i>	-1.70554	0.035225

351
352
353
354
355
356
357
358
359
360

361 **Table 4. List of top 10 DEGs enriched in BEC and LEC clusters following *L. major***
 362 **infection.**

A			B		
<u>BEC</u>			<u>LEC</u>		
Gene name	Avg. log-fold change	Adj. p value	Gene name	Avg. log-fold change	Adj. p value
Upregulated			Upregulated		
<i>B2m</i>	1.330157	3.83E-45	<i>B2m</i>	1.81363722	1.46E-39
<i>H2-K1</i>	1.134934	4.90E-39	<i>H2-K1</i>	1.82143009	6.52E-33
<i>H2-Aa</i>	1.483775	2.02E-27	<i>liqp1</i>	2.05863878	8.72E-22
<i>Cd74</i>	1.574517	1.16E-22	<i>Gbp4</i>	1.88908626	2.96E-21
<i>Gbp4</i>	1.127162	1.23E-21	<i>H2-D1</i>	1.07551012	1.24E-20
<i>Gbp2</i>	1.442935	3.36E-19	<i>Gbp2</i>	1.89596591	3.54E-18
<i>igtp</i>	1.08015	2.13E-17	<i>H2-Q7</i>	1.26192971	3.25E-17
<i>H2-Ab1</i>	1.277568	1.37E-16	<i>Gbp7</i>	1.31819045	3.86E-17
<i>Ctss</i>	1.372639	3.69E-16	<i>H2-Aa</i>	1.24429821	3.81E-15
<i>Ubd</i>	1.905291	9.22E-15	<i>H2-Ab1</i>	1.1254732	1.38E-13
Down regulated			Down regulated		
<i>Rpl9</i>	-0.7283	2.97E-16	<i>Rpl21</i>	-0.82606	1.30E-25
<i>Cxcl12</i>	-0.84167	6.72E-16	<i>Rpl13</i>	-0.86409	6.46E-24
<i>Rpl21</i>	-0.58083	7.74E-14	<i>Rpl30</i>	-0.74324	4.82E-19
<i>Rpl13</i>	-0.62302	2.34E-13	<i>Rps23</i>	-0.71284	2.88E-18
<i>Cst3</i>	-0.69511	1.61E-11	<i>Rps18</i>	-0.74298	5.32E-18
<i>Rps14</i>	-0.43341	2.62E-09	<i>Rps11</i>	-0.62415	4.34E-14
<i>Rpl18</i>	-0.563	1.25E-08	<i>Rpl9</i>	-0.78012	5.04E-14
<i>Rps15a</i>	-0.51256	1.51E-08	<i>Rps25</i>	-0.68713	7.72E-13
<i>Rpl30</i>	-0.51597	1.72E-08	<i>Rps4x</i>	-0.54557	1.19E-12
<i>Rps18</i>	-0.51715	2.05E-08	<i>Rpl11</i>	-0.63287	3.41E-12

380
381
382
383

384 In addition, many chemokines were differentially modulated in myeloid cells and
385 ECs with *L. major* infection (Fig 7). Specifically, *Cxcl9* was significantly elevated in
386 macrophages, resident macrophages, inflammatory monocytes, DCs, BECs, and
387 LECs following *L. major* infection (Fig 7 and Fig S3). In contrast, we found significant
388 downregulation of *Ccl24* in resident macrophages, *Cxcl12* in BECs, and *Ccl17* in DCs
389 following *L. major* infection (Fig 7B, 7E and Fig S3). Also important in immune cell
390 recruitment, selectins (*Selp*, *Sele*) and adhesion molecules (*Vcam1*) were significantly
391 upregulated in BECs with infection, while tight junction molecules like *Cldn5* were
392 downregulated (Fig 7E). Of note, known canonical markers were significantly elevated
393 with *L. major* infection including *Arg1*, *Nos2*, and *Pla2g7* in macrophages, *Fcgr4*, *C3*,
394 and *Ccl8* in resident macrophages, and *Ifitm1*, *Syng2*, *Cd200*, *Ccr7* in DCs (data not
395 shown). The complete list of DEGs that are enriched during *L. major* infection from
396 other cell type clusters such as fibroblasts, keratinocytes, chondrocytes, sebaceous
397 glands, basophils, upper hair follicle cells, pericytes, schwann cells, mast cells,
398 myocytes and myoblasts can be found in Gene Expression Omnibus database with
399 the GEO accession number - GSE181720.

400

401 **Characterization of upstream gene regulators and canonical** 402 **pathways during *L. major* infection in vivo**

403 To determine the cellular and biological mechanisms at the molecular level during *L.*
404 *major* infection, IPA analysis was performed to define the gene signature for each
405 individual cell type at the site of infection. IPA analysis of our scRNA-Seq data revealed
406 several known and unknown canonical pathways, upstream regulators, and disease-
407 based functional networks. Here, we present the genes that are significantly altered

408 (adj. p value < 0.05) in macrophages, BECs, and LECs from infected ears compared
409 to naive controls.

410 **Upstream gene regulators:** Our IPA analysis on macrophages, BECs, and
411 LECs revealed potential transcription factors as well as transcriptional targets like anti-
412 and pro-inflammatory genes. In macrophages, we observed 651 upstream regulators
413 in total which include 38 upregulated and 17 downregulated gene regulators. We found
414 cytokines like *IFN γ* , *IL-4*, *IL-13*, *IFN β 1*, *TNF α* , and transcriptional regulators such as
415 *HIF1 α* , *STAT1*, *CTCF*, *TP73*, *IRF1*, *MXD1*, *ATF4*, *SPI1* mediate macrophage
416 activation upon infection (Table 5). In contrast, transcriptional regulators like *MLXIPL*,
417 *MYC*, *TP53*, *MYCL*, *CEBPB*, *GATA1* were inhibited and no cytokines were identified
418 to downregulate macrophages activation following infection (Table 5). We identified
419 32 regulators were activated and 64 regulators were inhibited with infection in BECs.
420 The upregulated cytokines activating BECs included *IFN γ* , *TNF*, *IL-2*, *IL-4*, while *IL-10*
421 downregulates BEC activation (Table 6). Additionally, we found transcriptional
422 regulators that are either activated (*IRF3*, *STAT1*, *IRF7*, *MXD1*) or inhibited (*MLXIPL*,
423 *MYC*, *TRIM24*, *TP53*, *SIRT1*, *HSF1*, *MYCL*, *GLIS2*, *CEBPB*, *NFE2L2*) in BECs
424 following infection (Table 6). Likewise, 212 upstream regulators were detected of LECs
425 including 17 activated and 23 inhibited regulators. Corresponding to BECs, *IFN γ*
426 increases LEC activation, while *IL-10* downregulates LEC activation upon infection
427 (Table 7). In the LECs, we detected activated transcriptional regulators such as *IRF3*,
428 *STAT1*, and *IRF7*; however, *MLXIPL*, *MYC*, *TRIM24*, *TP53*, *SIRT1*, *MYCL*, *TARDBP*,
429 *STAT6*, *AIRE*, *LDB1*, *HNF4A*, and *NFE2L2* were inhibited in LECs comparing infected
430 mice to naive controls (Table 7).

431

432 **Table 5. List of top 5 upstream regulators identified in macrophages by IPA**
 433 **analysis for *L. major* infected ears.**

Predicted activation state	Upstream regulator	Activation z-score	p-value of overlap	No of target molecules in dataset
Cytokines				
Activated	<i>IFNG</i>	4.44	9.87E-19	36
	<i>IL4</i>	2.433	1.31E-11	28
	<i>IL13</i>	2.713	8.71E-09	11
	<i>IFNβ1</i>	2.383	0.0000127	10
	<i>TNF</i>	3.364	0.0000372	12
Inhibited	Not detected	-	-	-
Transcription regulators				
Activated	<i>HIF1A</i>	2.075	1.62E-08	13
	<i>STAT1</i>	2.396	6.09E-08	12
	<i>CTCF</i>	2.236	5.05E-06	5
	<i>TP73</i>	2.333	5.53E-06	10
	<i>IRF1</i>	2.383	0.0000841	6
Inhibited	<i>MLXIPL</i>	-8.062	1.2E-88	65
	<i>MYC</i>	-7.457	3.77E-82	71
	<i>TP53</i>	-2.227	1.77E-19	51
	<i>MYCL</i>	-2.97	7.63E-07	9
	<i>CEBPB</i>	-2.54	0.0000174	16

434 **Note:** The activation Z-Scores (-8.062 to 4.44) and p-values were < 0.05.

435

436 **Table 6. List of top 5 upstream regulators identified in BECs by IPA analysis for *L.***
 437 ***major* infected ears.**

Predicted activation state	Upstream regulator	Activation z-score	p-value of overlap	No of target molecules in dataset
<u>Cytokines</u>				
Activated	<i>IFNG</i>	3.684	5.19E-14	23
	<i>TNF</i>	2.99	5.79E-10	14
	<i>IL-2</i>	2.449	0.000141	7
	<i>IL-4</i>	2.219	0.00156	10
Inhibited	<i>IL-10</i>	-2.01	1.35E-11	14
<u>Transcription regulators</u>				
Activated	<i>IRF3</i>	3.065	2.11E-09	10
	<i>STAT-1</i>	2.377	1.37E-08	10
	<i>IRF7</i>	2.573	3.74E-07	7
	<i>MXD1</i>	2.0	0.00129	4
Inhibited	<i>MLXIPL</i>	-5.881	3.7E-48	36
	<i>MYC</i>	-5.207	3.54E-43	38
	<i>TRIM24</i>	-2.879	9.58E-12	12
	<i>TP53</i>	-3.877	1.8E-11	28
	<i>SIRT1</i>	-3.357	1.73E-10	15

438 **Note:** The activation Z-Scores (-5.881 to 3.684) and p-values were < 0.05.

439

440 **Table 7. List of top 5 upstream regulators identified in LECs by IPA analysis for *L.***
 441 ***major* infected ears.**

Predicted activation state	Upstream regulator	Activation z-score	p-value of overlap	No of target molecules in dataset
<u>Cytokines</u>				
Activated	<i>IFNG</i>	3.644	1.62E-07	14
Inhibited	<i>IL-10</i>	-2.219	4.28E-07	9
<u>Transcription regulators</u>				
Activated	<i>STAT-1</i>	2.766	3.47E-12	12
	<i>IRF3</i>	3.266	9.08E-12	11
	<i>IRF7</i>	2.795	2.97E-09	8
Inhibited	<i>MLXIPL</i>	-6.97	2.47E-80	49
	<i>MYC</i>	-6.714	1.82E-68	49
	<i>SIRT1</i>	-4.338	8.72E-17	19
	<i>TRIM24</i>	-3.564	2.14E-14	13
	<i>MYCL</i>	-2.97	4.91E-10	9

442 **Note:** The activation Z-Scores (-6.97 to 3.644) and p-values were < 0.05.

443

444

445 **Canonical pathways:** IPA analysis highlighted an unknown role for eukaryotic
446 translation initiation factor 2 (EIF2) signaling which includes large ribosomal proteins
447 (Rpl) and small ribosomal proteins (Rps) that were significantly downregulated with
448 infection compared to naive animals (Fig 8). Remarkably, the EIF2 pathway was the
449 top downregulated pathway amongst multiple cell types including macrophages
450 (Ranked as 1 amongst 377), BECs (Ranked as 1 amongst 257), and LECs (Ranked
451 as 1 amongst 145) (Fig 8A, C & E). This was followed by an involvement of mTOR
452 signalling and eIF4/p70S6K signalling in macrophages, BECs, and LECs from infected
453 ears. Alongside the IPA pathway results, the expression of individual transcripts for
454 each of the corresponding pathways is provided for macrophages (Fig 8B), BECs (Fig
455 8D), and LECs (Fig 8F). These data show the top 10 transcripts in the EIF2 signalling
456 pathway in macrophages, BECs, and LECs, which includes many subunits of
457 ribosomal proteins and these transcripts are mostly downregulated in the infected ears
458 compared to naive controls (Fig 8B, D & F). In contrast, the IPA analysis revealed the
459 antigen presentation pathway was increased with infection, and this pathway was also
460 a common feature of infection being the top elevated pathway for macrophages,
461 BECs, and LECs (Fig 8B, D & F). The antigen presentation pathway was enriched in
462 transcripts such as *B2m*, *Cd74*, *H2-K1*, *H2-Aa*, *H2-Ab1*, *H2-Eb1* that were elevated
463 with *L. major* infection in macrophages, BECs, and LECs. In addition to macrophages,
464 BECs, and LECs, we also noted that an involvement of mTOR signalling pathway is
465 consistent among the other immune cell types apart of this study such as inflammatory
466 monocytes, DCs, and CD4⁺ T cells, as mTOR signalling is top 5 in the list of pathways
467 (Fig S5). In summary, EIF2 signaling is the top downregulated pathway in BECs,
468 LECs, macrophages, as well as other immune cell types from infected ears.

469

470 Discussion

471 We conducted a comprehensive high-resolution transcriptomic analysis using both
472 bulk and scRNA-Seq approaches to discover the global changes in the gene
473 expression that occurs following *L. major* infection in vivo. Through our bulk RNA-Seq
474 analyses, we identified many differentially regulated novel transcripts in immune
475 compartments that are related to host immune response pathways. We found
476 significant enrichment of DEGs in the antigen processing and presentation pathway
477 following *L. major* infection. Specifically, our data indicate that *L. major* infection
478 upregulates many MHC molecules belonging to the antigen processing and
479 presentation pathway along with inflammatory cytokines such as *IFN* γ following *L.*
480 *major* infection. These findings are consistent with the well-established role of the Th1
481 immune response in parasite control; we confirm antigen presentation is a critical
482 process in host defense to *Leishmania* infection(48–53). Additionally, we noted the
483 enrichment of DEGs specific for other host immune response pathways such as
484 chemokine signalling, cell adhesion molecules, and cytokine-cytokine receptor
485 interactions in infected ears. In contrast, our bulk RNA-Seq results revealed DEGs
486 associated with the ribosomal pathway were downregulated following *L. major*
487 infection. While the importance of the downregulation of transcripts that encode 40S
488 and 60S ribosomal subunits has not been studied in *Leishmania*, these findings
489 suggest cells at the site of infection are actively controlling translation and/or
490 ribogenesis or undergoing a stress response similar to bacterial, viral infection and
491 cancer(54–56). Altogether, our bulk RNA-Seq results confirm a known role for the
492 importance of antigen presentation and highlight an unknown feature of
493 downregulating ribosomal subunits in CL.

494 Our scRNA-Seq analysis revealed many novel transcripts from various cell
495 types that remain largely unexplored at the site of *L. major* infection. Through our
496 scRNA-Seq data, we defined 35 distinct cell type populations by using canonical
497 markers specific for different cell types including both resident and recruited cells
498 following *L. major* infection. In agreement with previously published results(10,20), our
499 scRNA-Seq analysis confirmed a significant increase in various immune cell types at
500 the site of infection with recruited myeloid cells such as neutrophils, inflammatory
501 monocytes, and macrophages in lesions (Fig. 6). The transcriptional signature of
502 interferon-induced GTPases like GBPs were significantly upregulated in
503 macrophages, resident macrophages, inflammatory monocytes, DCs, BECs, and
504 LECs following *L. major* infection. These data suggest GBPs may play a protective
505 role in both immune and nonimmune cells during *L. major* infection. GBPs are involved
506 in controlling intracellular pathogen replication and specifically mediating the
507 protection against intracellular pathogens such as *Listeria monocytogenes* and
508 *Mycobacterium bovis*(57) (58). Importantly, mice deficient in GBP genes are more
509 susceptible to *Toxoplasma gondii*(59). Moreover, GBPs restrict *L. donovani* growth in
510 nonphagocytic cells such as murine embryonic fibroblasts in an IFN γ -dependent
511 manner(60).

512 We detected several transcripts for chemokines (*Cxcl9*, *Cxcl10*) in myeloid cells
513 that are elevated with infection that may mediate myeloid cell accumulation at the site
514 of infection. Our results revealed a significant downregulation of *Ccl24* transcript in
515 resident macrophages from infected ears compared to naive controls. A recent study
516 demonstrated dermal tissue-resident macrophages shift toward a pro-inflammatory
517 state in *L. major*-infected mice lacking IL-4/IL-13 from eosinophils, which is mainly
518 regulated by CCL24 from resident macrophages(61). Also, potentially mediating

519 myeloid cell migration, we found BECs in infected skin express elevated transcripts
520 for selectins (*Sele*, *Selp*) and adhesion molecules (*Vcam1*), while concomitantly
521 downregulating transcripts responsible for junctional stability. Mice doubly deficient in
522 E- and P-selectin develop significantly less inflammation following *L. major*
523 infection(62). Taken with our findings, these data suggest BECs play an active role
524 during CL to recruit immune cells into the site of infection. Indeed, these scRNA-Seq
525 data also correlate with our bulk RNA-Seq results which indicate a role of leukocyte
526 trans-endothelial migration pathway in infected ears when compared to naive controls.
527 Overall, our scRNA-Seq data reveals cells in leishmanial lesions exist in pro-
528 inflammatory environment, but the actual host protective role of individual DEGs within
529 each cell type requires further investigation.

530 We detected the presence of *L. major* transcripts in multiple cell types including
531 myeloid cells like macrophages, neutrophils, and DCs which are all known to harbor
532 parasites(47,63,64). We also detected *L. major* transcripts in stromal cells such as
533 fibroblasts and keratinocytes, which can be infected by parasites(65,66). Surprisingly,
534 we also found evidence of parasite transcripts in myoblasts, chondrocytes, and BECs
535 which has not previously been reported. Importantly, the molecular techniques used
536 in these studies cannot differentiate between living and dead parasites and we can
537 only report cells harboring parasite transcripts. Therefore, subsequent studies will
538 need to determine if parasites in other non-myeloid cells like myoblasts and BECs are
539 viable and capable of replication and infection. Others have hypothesized *Leishmania*
540 parasites might evade the host immune responses by seeking shelter in different non-
541 macrophage cell types including fibroblasts and keratinocytes in addition to infection
542 in neutrophils, macrophages and DCs which exhibit a more robust pro-inflammatory
543 response against *Leishmania* parasites(67). However, the presence of *L. major*

544 transcripts from non-myeloid stromal cell types like myoblasts and BECs needs to be
545 further explored to determine whether these cells can serve as safe havens for *L.*
546 *major* parasites during chronic infection or provide a conduit for metastasis.
547 Regardless, these results shed light on cell types previously not thought to harbor
548 *Leishmania* parasites in the skin and provide an opportunity for new investigation.

549 Macrophages are the replicative niche for the parasite as well as the major cell
550 type responsible for parasite control. BECs play a crucial role in regulating immune
551 cell entry into inflamed tissues and LECs participate in immune cell migration out of
552 the lesions. As a result of the critical roles of these cell types during *L. major* infection,
553 we focused on identifying the upstream regulators and canonical pathways for
554 macrophages, BECs, and LECs. Surprisingly, the antigen processing and
555 presentation pathway and EIF2 signaling were the most significant pathways in all
556 three cell types (macrophages, BECs, and LECs) within infected ears. The antigen
557 processing and presentation showed a positive activation z score indicating overall
558 upregulation of the pathway, which is consistent with findings in human CL lesions(68).
559 Immunoproteasomes play a critical role in the immune response by degrading
560 intracellular proteins to generate MHC I epitopes for effective antigen presentation(69).
561 While the increased expression of immunoproteasome genes in human lesions
562 caused by *L. braziliensis* infection has been reported(68), our results reveal for the
563 first time that LECs express higher levels of transcripts for immunoproteasomes
564 (*psmb8* and *psmb9*), as well as transcripts involved in the antigen presentation
565 pathway (*Tap1* and *Tapbp*) following *L. major* infection. These data suggest that ECs,
566 and specifically LECs, may play an unknown role in antigen presentation during *L.*
567 *major* infection, similar to viral infection and vaccination(69,70).

568 The EIF2 signaling pathway had the highest negative activation z score of all
569 the pathways indicating overall deregulation during CL. To our knowledge, this is the
570 first study highlighting EIF2 signaling as a novel candidate pathway for leishmaniasis.
571 Eukaryotic initiation factor-2 (EIF2) is a GTP-binding protein, which initiates protein
572 translation by delivering charged initiator met-tRNA onto the ribosome(71). Upon
573 subject to infection-induced cellular stress, EIF2 plays a significant role in attenuating
574 translation initiation by phosphorylation of the alpha subunit of eIF2 leading to
575 immediate shut-off of translation and activation of stress response genes(71).
576 Phosphorylation of eIF2 α plays as a rate limiting step as it reduces active eIF2-GTP
577 levels at translation initiation which ultimately results in a global reduction of protein
578 synthesis(71,72). Our data indicate that impaired EIF2 signaling is linked to the
579 downregulation of many ribosomal subunits in macrophages, BECs, and LEC in *L.*
580 *major*-infected ears (Fig. 8). The known phenomenon of “protein shut off” has been
581 well described at the molecular level for some viruses(73), but there is little to no
582 evidence documenting this phenomenon during *L. major* infection. Generally, the
583 enhanced host response to viral and bacterial infections depends on the upregulation
584 of EIF2-mediated translational control, thereby reducing general protein
585 synthesis(55,56,73). However, we found EIF2 signaling was downregulated with *L.*
586 *major* infection. Previously it was demonstrated that *L. major* promotes its survival by
587 downregulating macrophage protein synthesis, which is mainly mediated by host
588 translation repressor 4E-BP1(74). Given the robust production of cytokines and
589 chemokines in leishmanial lesions, global protein synthesis does not seem impacted
590 by *L. major* infection in vivo, but careful analysis of EIF2 signaling has not been
591 performed to date.

592 Alongside EIF2 signalling, the involvement of mTOR and eIF4/p70S6K
593 signalling in macrophages, BECs, and LECs in infected mice hints at an important role
594 for hypoxia-induced oxidative stress at the site of *L. major* infected ears. Our results
595 indicate the activation of metabolic gene targets like hypoxia-inducible factor (HIF-1 α)
596 in macrophages, which is consistent with our previous results and work by the Jantsch
597 lab showing leishmanial lesions are hypoxic(75–77). Therefore, we speculate EIF2
598 signaling is downregulated as part of the stress response, potentially from hypoxia,
599 but mechanism by which EIF2 signaling is impaired in multiple cell types and how that
600 contributes to pathogen control or the pathogenesis of disease in CL is unknown.
601 Collectively, our transcriptome analysis not only provides the first comprehensive list
602 of gene expression at single-cell resolution, but also highlights a previously unknown
603 role of the highly conserved EIF2 signaling pathway in leishmaniasis. Future analysis
604 by us and others utilizing these datasets will expand our knowledge on the complex
605 immune networks and pathways participating in the host response to *Leishmania*
606 infection.

607

608 **Materials and methods**

609 **Animals**

610 Female C57BL/6NCr mice were purchased from the National Cancer Institute. Mice
611 were housed in the Division of Laboratory Animal Medicine at University of Arkansas
612 for Medical Sciences (UAMS) under pathogen-free conditions and used for
613 experiments between 6 and 8 weeks of age. All procedures were performed in
614 accordance with the guidelines of the UAMS Institutional Animal Care and Use
615 Committee (IACUC).

616 **Parasite Infection in vivo**

617 *Leishmania major* (WHO/MHOM/IL/80/Friedlin) strain was used. Parasites were
618 maintained in vitro in Schneider's Drosophila medium (Gibco) supplemented with 20%
619 heat-inactivated FBS (Invitrogen), 2 mM L-glutamine (Sigma), 100 U/mL penicillin, and
620 100 mg/mL streptomycin (Sigma). Metacyclic stationary phase promastigotes were
621 isolated from 4–5 day cultures by Ficoll density gradient separation (Sigma). For ear
622 dermal infections, 2×10^6 *L. major* promastigote parasites in 10 μ L PBS (Gibco) were
623 injected intradermally into the ear. Lesion development was monitored weekly by
624 measuring ear thickness and lesion area with a caliper. Lesion volume was calculated.
625 At 4-week post infection, ears were excised and enzymatically digested using 0.25
626 mg/mL Liberase (Roche) and 10 mg/mL DNase I (Sigma) in incomplete RPMI 1640
627 (Gibco) for 90 min at 37°C. After digesting, ears were minced manually to obtain
628 cellular content in single cell suspensions. Parasite burdens were determined by
629 limiting dilution assays (LDAs), as previously described(78).

630

631 **Bulk RNA-Seq: Sample Preparation**

632 The total RNA was isolated from the cell lysate of naive and infected ears by using
633 Qiagen's RNeasy plus mini kit according to the manufacturer's instructions. The CTPR
634 Genomics and Bioinformatics Core at the Arkansas Children's Research Institute
635 (ACRI) prepared sequencing libraries from RNA samples by use of the Illumina
636 TruSeq Stranded mRNA Sample Preparation Kit v2. for sequencing on the NextSeq
637 500 platform using Illumina reagents. The quality and quantity of input RNA was
638 determined using the Advanced Analytical Fragment Analyzer (AATI) and Qubit (Life
639 Technologies) instruments, respectively. All samples with RQN (RNA quality number)
640 values of 8.0 or above were processed for sequencing. Sequencing libraries were
641 prepared by use of the TruSeq Stranded mRNA Sample Prep Kit (Illumina). Briefly,
642 total RNA (500 ng) was subjected to polyA selection, then chemically fragmented and
643 converted to single-stranded cDNA using random hexamer primed reverse
644 transcription. The second strand was generated to create double-stranded cDNA,
645 followed by fragment end repair and addition of a single A base on each end of the
646 cDNA. Adapters were ligated to each fragment end to enable attachment to the
647 sequencing flow cell. The adapters also contain unique index sequences that allow
648 the libraries from different samples to be pooled and individually identified during
649 downstream analysis. Library DNA was PCR amplified and enriched for fragments
650 containing adapters at each end to create the final cDNA sequencing library. Libraries
651 were validated on the Fragment Analyzer for fragment size and quantified by use of a
652 Qubit fluorometer. Equal amounts of each library was pooled for sequencing on the
653 NextSeq 500 platform using a high output flow cell to generate approximately 25
654 million 75 base reads per sample.

655 **Bulk RNA-Seq: Data Analysis**

656 Following demultiplexing, RNA reads were checked for sequencing quality using
657 FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>) and MultiQC(79)
658 (version 1.6). The raw reads were then processed according to Lexogen's QuantSeq
659 data analysis pipeline with slight modification. Briefly, residual 3' adapters, polyA read
660 through sequences, and low quality ($Q < 20$) bases were trimmed using BBTools
661 BBDuk (version 38.52) (<https://sourceforge.net/projects/bbmap/>). The first 12 bases
662 were also removed per the manufacture's recommendation. The cleaned reads (\geq
663 20bp) were then mapped to the mouse reference genome (GRCm38/mm10/ensemble
664 release-84.38/ [GCA_000001635.6](https://www.ncbi.nlm.nih.gov/assembly/GCA_000001635.6)) using STAR(80) (version 2.6.1a), allowing up to 2
665 mismatches depending on the alignment length (e.g. 20-29bp, 0 mismatches; 30-
666 50bp, 1 mismatch; 50-60+bp, 2 mismatches). Reads mapping to > 20 locations were
667 discarded. Gene level counts were quantified using HTSeq (htseq-counts)(81)
668 (version 0.9.1) (mode: intersection-nonempty).

669 Genes with unique Entrez IDs and a minimum of ~ 2 counts-per-million (CPM)
670 in 4 or more samples were selected for statistical testing. This was followed by scaling
671 normalization using the trimmed mean of M-values (TMM) method(82) to correct for
672 compositional differences between sample libraries. Differential expression between
673 naive and infected ears was evaluated using limma voomWithQualityWeights(83) with
674 empirical bayes smoothing. Genes with Benjamini & Hochberg(84) adjusted p-values
675 ≤ 0.05 and absolute fold-changes ≥ 1.5 were considered significant.

676 Gene Set Enrichment Analysis (GSEA) was carried out using Kyoto
677 Encyclopedia of Genes and Genomes (KEGG) pathway databases and for each
678 KEGG pathway, a p-value was calculated using hypergeometric test. Cut-off of both p
679 < 0.05 and adjusted p-value/FDR value < 0.05 was applied to identify enriched KEGG

680 pathways. DEGs that are more than 1.5-fold in *L. major*-infected ears relative to
681 uninfected controls were used as input, with upregulated and downregulated genes
682 considered separately. Subsequently, the heat maps were generated using these
683 genes with complex Heatmap. All analyses and visualizations were carried out using
684 the statistical computing environment R version 3.6.3, RStudio version 1.2.5042, and
685 Bioconductor version 3.11. The raw data from our bulk RNA-Seq analysis were
686 deposited in Gene Expression Omnibus (GEO accession number - GSE185253).

687 **scRNA-Seq Sample Preparation**

688 The Genomics and Bioinformatics Core at the Arkansas Children's Research Institute
689 (ACRI) prepared NGS libraries from fresh single-cell suspensions using the 10X
690 Genomics NextGEM 3' assay for sequencing on the NextSeq 500 platform using
691 Illumina SBS reagents. The quantity and viability of cells input to the assay was
692 determined using Trypan Blue exclusion under 10X magnification. Library quality was
693 assessed with the Advanced Analytical Fragment Analyzer (Agilent) and Qubit (Life
694 Technologies) instruments.

695 **scRNA-Seq Data Analysis**

696 Demultiplexed fastq files generated by the UAMS Genomics Core were analyzed with
697 the 10x Genomics Cell Ranger alignment and gene counting software, a self-
698 contained scRNA-Seq pipeline developed by 10X Genomics. The reads are aligned
699 to the mm10 and *Leishmania major* reference transcriptomes using STAR and
700 transcript counts are generated(80,85) .

701 The raw counts generated by *cellranger count* were further processed using the
702 R package *Seurat*(86,87). Low quality cells, potential cell doublets, and cells with high
703 percentage of mitochondrial genes were filtered out of the data. We filtered cells that

704 have unique feature counts over more the 75th percentile plus 1.5 times the
705 interquartile range (IQR) or less than the 25th percentile minus 1.5 time the IQR.
706 Additionally, we filtered cells with mitochondrial counts falling outside the same range
707 with respect to mitochondrial gene percentage. Following filtering the counts all 8
708 sequencing runs were merged. The counts are then normalized using the
709 LogNormalize method, which normalizes the feature expression measurements for
710 each cell by the total expression, multiplies this by a scale factor (10,000 by default),
711 and log-transforms the result. Next, the 2000 highest variable features are selected.
712 The data is then scaled, and linear regression is included to remove variation
713 associated with percent mitochondria and cell cycle status. Principle component
714 analysis (PCA) is performed on the scaled data. A JackStraw procedure was
715 implemented to determine the significant PCA components that have a strong
716 enrichment of low p-value features.

717 A graph-based clustering approach is applied(88). Briefly, these methods
718 embed cells in a graph structure - for example a K-nearest neighbor (KNN) graph, with
719 edges drawn between cells with similar feature expression patterns, and then attempt
720 to partition this graph into highly interconnected 'quasi-cliques' or 'communities'. t-
721 distributed stochastic neighbor embedding (tSNE) and Uniform Manifold
722 Approximation and Projection (UMAP)(89) are non-linear dimensional reduction
723 techniques used to visualize and explore the results and are performed using Seurat.
724 Seurat *FindNeighbors* and *FindClusters* functions will be optimized to label clusters
725 based on the visual clustering in the projections. Seurat *FindAllMarkers* function finds
726 markers that define clusters by differential expression. It identifies positive markers of
727 a single cluster compared to all other cells and outputs the differential expression
728 results. These markers will be compared to known markers of expected cell types and

729 results from previous single-cell transcriptome studies in order to assign appropriate
730 cell type labels. Cell type determinations were made by manually expecting these
731 results and some clusters were combined if their expression was found to be similar.
732 Differential expression analysis will be performed using MAST, a GLM-framework that
733 treats cellular detection rate as a covariate(90). The raw data from our scRNA-Seq
734 analysis were deposited in Gene Expression Omnibus (GEO accession number -
735 GSE181720)

736 **Ingenuity Pathway Analysis (IPA)**

737 QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood
738 City, www.qiagen.com/ingenuity) was utilized to investigate the DEGs at the level of
739 biochemical pathways and molecular functions. We submitted our DEGs to functional
740 analysis with IPA, and IPA provided canonical pathways, diseases and function, and
741 upstream regulators based on the experimentally observed cause-effect relationships
742 related to transcription, expression, activation, molecular modification, etc. Z-score
743 analyses are used to assess the match between observed and predicted up and down
744 regulation patterns allowing for Bayesian scoring of the results.

745 **Flow Cytometry Analysis with Statistics**

746 The recruitment of immune cells during *L. major* infection was analyzed by flow
747 cytometry. Cells from both naive and infected ears were incubated with fixable Aqua
748 dye (Invitrogen) to assess cell viability, and cells were treated with FcγR blocking
749 reagent (Bio X Cell) prior to staining for the following markers: anti-CD45-AF700
750 (clone 30-F11), anti-Ly6C-PerCP-Cy5.5 (clone HK1.4), and anti-Ly6G-eFlour 450
751 (clone 1A8) were purchased from eBiosciences; anti-CD64-BV711 (clone X54-5/7.1),
752 anti-CD11b-BV605 (clone M1/70), anti-CD31-AF488 (390), and anti-podoplanin-

753 PE/Dazzle 594 (clone 8.1.1) were purchased from BioLegend. Cells were acquired
754 using an LSR II Fortessa flow cytometer (BD Biosciences) and analyzed using FlowJo
755 software version 10.2 (Tree Star). All statistical analyses were performed using Prism
756 version 8.0 (GraphPad Software, Inc.). Comparisons between groups were performed
757 using the two-tailed Students unpaired *t*-test.

758

759 **Acknowledgements and funding sources**

760 The authors would like to thank Dr. Lu Huang, the Huang lab, Lucy Fry and Conner
761 Webb for their critical reading of the manuscript. We would like to thank the veterinary
762 staff from the Division of Laboratory Animal Medicine (DLAM) and Andrea Harris from
763 Flow cytometry core facility at UAMS for their excellent technical assistance. This work
764 was supported by the Center for Microbial Pathogenesis and Host Inflammatory
765 Responses (funded by National Institutes of Health National Institute of General
766 Medical Sciences Centers of Biomedical Research Excellence Grant P20-GM103625)
767 and the Oak Ridge Associated Universities (ORAU) 2019 Ralph E. Powe Junior
768 Faculty Enhancement Award to Dr. Weinkopff. This work was also supported by the
769 UAMS Translational Research Institute in collaboration with the UAMS Division for
770 Diversity, Equity and Inclusion (DDEI) Mini Grants for Under-Represented Faculty
771 Researchers to Dr. Weinkopff as part of the NIH National Center for Advancing
772 Translational Sciences (NCATS), UL1-TR003107. This study was supported by the
773 Arkansas Children's Research Institute, the Arkansas Biosciences Institute, and the
774 Center for Translational Pediatric Research funded under the National Institutes of
775 Health National Institute of General Medical Sciences (NIH/NIGMS) grant
776 P20GM121293 and the National Science Foundation Award No. OIA-1946391. The
777 funders had no role in study design, data analysis, decision to publish or preparation
778 of the manuscript.

779 **Competing interests:**

780 The authors have declared that no competing interests exist.

781

782

783 **References**

- 784 1. Burza S, Croft SL, Boelaert M. Leishmaniasis. *Lancet*. 2018;392(10151):951–
785 70.
- 786 2. Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et
787 al. A second generation leishmanization vaccine with a markerless attenuated
788 *Leishmania major* strain using CRISPR gene editing. *Nat Commun*.
789 2020;11(1):1–14.
- 790 3. Kaye PM, Cruz I, Picado A, Van Bocxlaer K, Croft SL. Leishmaniasis
791 immunopathology—impact on design and use of vaccines, diagnostics and
792 drugs. *Seminars in Immunopathology*. 2020.
- 793 4. Laskay T, Van Zandbergen G, Solbach W. Neutrophil granulocytes - Trojan
794 horses for *Leishmania major* and other intracellular microbes? *Trends*
795 *Microbiol*. 2003;11(5):210–4.
- 796 5. Ribeiro-Gomes FL, Sacks D. The influence of early neutrophil-*Leishmania*
797 interactions on the host immune response to infection. *Front Cell Infect*
798 *Microbiol*. 2012;2(May):59.
- 799 6. Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, et al.
800 In vivo imaging reveals an essential role for neutrophils in leishmaniasis
801 transmitted by sand flies. *Science (80-)*. 2008;
- 802 7. León B, López-Bravo M, Ardavín C. Monocyte-Derived Dendritic Cells Formed
803 at the Infection Site Control the Induction of Protective T Helper 1 Responses
804 against *Leishmania*. *Immunity*. 2007;26(4):519–31.
- 805 8. Charmoy M, Brunner-Agten S, Aebischer D, Auderset F, Launois P, Milon G,
806 et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic
807 cells to the site of *Leishmania major* inoculation in resistant mice. *PLoS*
808 *Pathog*. 2010;6(2).
- 809 9. Lai GN, Hsu A, Mandell MA, Roediger B, Hoeller C, Mrass P, et al. Migratory
810 dermal dendritic cells act as rapid sensors of protozoan parasites. *PLoS*
811 *Pathog*. 2008;4(11).

- 812 10. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to
813 *Leishmania major* in mice. *Nat Rev Immunol*. 2002;2(11):845–58.
- 814 11. Scott P, Novais FO. Cutaneous leishmaniasis: Immune responses in
815 protection and pathogenesis. *Nat Rev Immunol*. 2016;16(9):581–92.
- 816 12. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which
817 *Leishmania* parasites can escape the host immune response: A signaling point
818 of view. *Clin Microbiol Rev*. 2005;18(2):293–305.
- 819 13. Kaye P, Scott P. Leishmaniasis: Complexity at the host-pathogen interface.
820 *Nat Rev Microbiol*. 2011;9(8):604–15.
- 821 14. Arenas R, Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J.
822 Leishmaniasis: A review. *F1000Research*. 2017;6(May):1–15.
- 823 15. Reithinger R. Cutaneous leishmaniasis. *Lancet Infect Dis*. 2007;146(7):581–
824 96.
- 825 16. Terabe M, Kuramochi T, Ito M, Hatabu T, Sanjoba C, Chang KP, et al. CD4+
826 cells are indispensable for ulcer development in murine cutaneous
827 leishmaniasis. *Infect Immun*. 2000;
- 828 17. Pereira L de OR, Moreira RB, de Oliveira MP, Reis S de O, de Oliveira Neto
829 MP, Pirmez C. Is *Leishmania* (*Viannia*) *braziliensis* parasite load associated
830 with disease pathogenesis? *Int J Infect Dis*. 2017;
- 831 18. Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S,
832 Carvalho LP, et al. IL-17 Mediates Immunopathology in the Absence of IL-10
833 Following *Leishmania major* Infection. *PLoS Pathog*. 2013;
- 834 19. Bittencourt AL, Barral A. Evaluation of the histopathological classifications of
835 American cutaneous and mucocutaneous leishmaniasis. Vol. 86, *Memórias do*
836 *Instituto Oswaldo Cruz*. 1991. p. 51–6.
- 837 20. Scott P, Novais FO. Cutaneous leishmaniasis: Immune responses in
838 protection and pathogenesis. *Nat Rev Immunol*. 2016;16(9):581–92.
- 839 21. Soong L, Chang CH, Sun J, Longley BJ, Ruddle NH, Flavell RA, et al. Role of
840 CD4+ T cells in pathogenesis associated with *Leishmania amazonensis*

- 841 infection. *J Immunol* [Internet]. 1997;158(11):5374–83. Available from:
842 <http://www.ncbi.nlm.nih.gov/pubmed/9164958>
- 843 22. Scorza BM, Carvalho EM, Wilson ME. Cutaneous manifestations of human
844 and murine leishmaniasis. *International Journal of Molecular Sciences*. 2017.
- 845 23. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et
846 al. The genome of the kinetoplastid parasite, *Leishmania major*. *Science* (80-).
847 2005;
- 848 24. Holzer TR, McMaster WR, Forney JD. Expression profiling by whole-genome
849 interspecies microarray hybridization reveals differential gene expression in
850 procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes
851 in *Leishmania mexicana*. *Mol Biochem Parasitol*. 2006;146(2):198–218.
- 852 25. Leifso K, Cohen-Freue G, Dogra N, Murray A, McMaster WR. Genomic and
853 proteomic expression analysis of *Leishmania* promastigote and amastigote life
854 stages: The *Leishmania* genome is constitutively expressed. *Mol Biochem*
855 *Parasitol*. 2007;152(1):35–46.
- 856 26. McNicoll F, Drummelsmith J, Müller M, Madore É, Boilard N, Ouellette M, et al.
857 A combined proteomic and transcriptomic approach to the study of stage
858 differentiation in *Leishmania infantum*. *Proteomics*. 2006;6(12):3567–81.
- 859 27. Walker J, Vasquez JJ, Gomez MA, Drummelsmith J, Burchmore R, Girard I, et
860 al. Identification of developmentally-regulated proteins in *Leishmania*
861 *panamensis* by proteome profiling of promastigotes and axenic amastigotes.
862 *Mol Biochem Parasitol*. 2006;147(1):64–73.
- 863 28. Saxena A, Lahav T, Holland N, Aggarwal G, Anupama A, Huang Y, et al.
864 Analysis of the *Leishmania donovani* transcriptome reveals an ordered
865 progression of transient and permanent changes in gene expression during
866 differentiation. *Mol Biochem Parasitol*. 2007;152(1):53–65.
- 867 29. Rochette A, Raymond F, Ubeda JM, Smith M, Messier N, Boisvert S, et al.
868 Genome-wide gene expression profiling analysis of *Leishmania major* and
869 *Leishmania infantum* developmental stages reveals substantial differences
870 between the two species. *BMC Genomics*. 2008;9:1–26.

- 871 30. Depledge DP, Evans KJ, Ivens AC, Aziz N, Maroof A, Kaye PM, et al.
872 Comparative expression profiling of Leishmania: Modulation in gene
873 expression between species and in different host genetic backgrounds. *PLoS*
874 *Negl Trop Dis.* 2009;3(7).
- 875 31. Chaussabel D, Semnani RT, McDowell MA, Sacks D, Sher A, Nutman TB.
876 Unique gene expression profiles of human macrophages and dendritic cells to
877 phylogenetically distinct parasites. *Blood* [Internet]. 2003;102(2):672–81.
878 Available from: <http://dx.doi.org/10.1182/blood-2002-10-3232>
- 879 32. Ettinger NA, Wilson ME. Macrophage and T-cell gene expression in a model of
880 early infection with the protozoan *Leishmania chagasi*. *PLoS Negl Trop Dis.*
881 2008;2(6).
- 882 33. Pollack JR. A perspective on DNA microarrays in pathology research and
883 practice. In: *American Journal of Pathology.* 2007.
- 884 34. Akopyants NS, Matlib RS, Bukanova EN, Smeds MR, Brownstein BH, Stormo
885 GD, et al. Expression profiling using random genomic DNA microarrays
886 identifies differentially expressed genes associated with three major
887 developmental stages of the protozoan parasite *Leishmania major*. *Mol*
888 *Biochem Parasitol.* 2004;136(1):71–86.
- 889 35. Shadab M, Das S, Banerjee A, Sinha R, Asad M, Kamran M, et al. RNA-Seq
890 Revealed Expression of Many Novel Genes Associated With *Leishmania*
891 *donovani* Persistence and Clearance in the Host Macrophage. *Front Cell Infect*
892 *Microbiol.* 2019;9(February):17.
- 893 36. Rastrojo A, Corvo L, Lombraña R, Solana JC, Aguado B, Requena JM.
894 Analysis by RNA-seq of transcriptomic changes elicited by heat shock in
895 *Leishmania major*. *Sci Rep.* 2019;9(1):1–18.
- 896 37. Ruy PDC, Monteiro-Teles NM, Miserani Magalhães RD, Freitas-Castro F, Dias
897 L, Aquino Defina TP, et al. Comparative transcriptomics in *Leishmania*
898 *braziliensis*: disclosing differential gene expression of coding and putative
899 noncoding RNAs across developmental stages. *RNA Biol* [Internet].
900 2019;16(5):639–60. Available from:

- 901 <https://doi.org/10.1080/15476286.2019.1574161>
- 902 38. Christensen SM, Dillon LAL, Carvalho LP, Passos S, Novais FO, Hughitt VK,
903 et al. Meta-transcriptome Profiling of the Human-*Leishmania braziliensis*
904 Cutaneous Lesion. *PLoS Negl Trop Dis*. 2016;10(9):1–17.
- 905 39. Amorim CF, Novais FO, Nguyen BT, Misic AM, Carvalho LP, Carvalho EM, et
906 al. Variable gene expression and parasite load predict treatment outcome in
907 cutaneous leishmaniasis. *Sci Transl Med*. 2019;11(519):1–10.
- 908 40. Patino LH, Muskus C, Ramírez JD. Transcriptional responses of *Leishmania*
909 (*Leishmania*) *amazonensis* in the presence of trivalent sodium stibogluconate.
910 *Parasites and Vectors* [Internet]. 2019;12(1):1–15. Available from:
911 <https://doi.org/10.1186/s13071-019-3603-8>
- 912 41. Fiebig M, Kelly S, Gluenz E. Comparative Life Cycle Transcriptomics Revises
913 *Leishmania mexicana* Genome Annotation and Links a Chromosome
914 Duplication with Parasitism of Vertebrates. *PLoS Pathog*. 2015;11(10):1–28.
- 915 42. Andrade JM, Gonçalves LO, Liarte DB, Lima DA, Guimarães FG, de Melo
916 Resende D, et al. Comparative transcriptomic analysis of antimony resistant
917 and susceptible *Leishmania infantum* lines. *Parasites and Vectors* [Internet].
918 2020;13(1):1–15. Available from: <https://doi.org/10.1186/s13071-020-04486-4>
- 919 43. Farias Amorim C, Novais FO, Nguyen BT, Nascimento MT, Lago J, Lago AS,
920 et al. Localized skin inflammation during cutaneous leishmaniasis drives a
921 chronic, systemic ifn- γ signature. *PLoS Negl Trop Dis* [Internet]. 2021;15(4):1–
922 19. Available from: <http://dx.doi.org/10.1371/journal.pntd.0009321>
- 923 44. Dillon LAL, Suresh R, Okrah K, Corrada Bravo H, Mosser DM, El-Sayed NM.
924 Simultaneous transcriptional profiling of *Leishmania major* and its murine
925 macrophage host cell reveals insights into host-pathogen interactions. *BMC*
926 *Genomics* [Internet]. 2015;16(1):1–15. Available from:
927 <http://dx.doi.org/10.1186/s12864-015-2237-2>
- 928 45. Fernandes MC, Dillon LAL, Belew AT, Bravo HC, Mosser DM, El-Sayed NM.
929 Dual transcriptome profiling of *Leishmania*-infected human macrophages
930 reveals distinct reprogramming signatures. *MBio*. 2016;7(3):1–16.

- 931 46. Franzén O, Gan LM, Björkegren JLM. PanglaoDB: A web server for
932 exploration of mouse and human single-cell RNA sequencing data. Database.
933 2019;
- 934 47. Walker DM, Oghumu S, Gupta G, Mcgwire BS, Drew ME, Satoskar AR.
935 Mechanisms of cellular invasion by intracellular parasites Mechanisms of host
936 cell invasion in Leishmania. *Cell Mol Life Sci.* 2014;71(7):1245–63.
- 937 48. Feijó D, Tibúrcio R, Ampuero M, Brodskyn C, Tavares N. Dendritic cells and
938 leishmania infection: Adding layers of complexity to a complex disease.
939 *Journal of Immunology Research.* 2016.
- 940 49. Kautz-Neu K, Schwonberg K, Fischer MR, Schermann AI, von Stebut E.
941 Dendritic cells in Leishmania major infections: mechanisms of parasite uptake,
942 cell activation and evidence for physiological relevance. *Medical Microbiology
943 and Immunology.* 2012.
- 944 50. Liu D, Kebaier C, Pakpour N, Capul AA, Beverley SM, Scott P, et al.
945 Leishmania major phosphoglycans influence the host early immune response
946 by modulating dendritic cell functions. *Infect Immun.* 2009;
- 947 51. Woelbing F, Kostka SL, Moelle K, Belkaid Y, Sunderkoetter C, Verbeek S, et
948 al. Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors
949 and facilitates acquisition of protective immunity. *J Exp Med.* 2006;
- 950 52. Axelrod O, Klaus S, Frankenburg S. Antigen presentation by epidermal
951 langerhans cells in experimental cutaneous leishmaniasis. *Parasite Immunol.*
952 1994;
- 953 53. Liu D, Uzonna JE. The early interaction of Leishmania with macrophages and
954 dendritic cells and its influence on the host immune response. *Frontiers in
955 cellular and infection microbiology.* 2012.
- 956 54. Chen X, Wu H, Feng J, Li Y, Lv J, Shi W, et al. Transcriptome profiling unveils
957 GAP43 regulates ABC transporters and EIF2 signaling in colorectal cancer
958 cells. *BMC Cancer.* 2021;21(1):1–10.
- 959 55. Toribio R, Ventoso I. Inhibition of host translation by virus infection in vivo.
960 *Proc Natl Acad Sci U S A.* 2010;107(21):9837–42.

- 961 56. Shrestha N, Bahnan W, Wiley DJ, Barber G, Fields KA, Schesser K.
962 Eukaryotic Initiation Factor 2 (eIF2) signaling regulates proinflammatory
963 cytokine expression and bacterial invasion. *J Biol Chem.* 2012;
- 964 57. Kim BH, Shenoy AR, Kumar P, Das R, Tiwari S, MacMicking JD. A family of
965 IFN- γ -inducible 65-kD GTPases protects against bacterial infection. *Science*
966 (80-). 2011;
- 967 58. Ngo CC, Man SM. Mechanisms and functions of guanylate-binding proteins
968 and related interferon-inducible GTPases: Roles in intracellular lysis of
969 pathogens. *Cellular Microbiology.* 2017.
- 970 59. Yamamoto M, Okuyama M, Ma JS, Kimura T, Kamiyama N, Saiga H, et al. A
971 cluster of interferon- γ -inducible p65 gtpases plays a critical role in host
972 defense against toxoplasma gondii. *Immunity.* 2012;
- 973 60. Haldar AK, Nigam U, Yamamoto M, Coers J, Goyal N. Guanylate binding
974 proteins restrict leishmania donovani growth in nonphagocytic cells
975 independent of parasitophorous vacuolar targeting. *MBio.* 2020;
- 976 61. Lee SH, Chaves MM, Kamenyeva O, Gazzinelli-Guimaraes PH, Kang B,
977 Pessenda G, et al. M2-like, dermal macrophages are maintained via IL-
978 4/CCL24-mediated cooperative interaction with eosinophils in cutaneous
979 leishmaniasis. *Sci Immunol.* 2020;
- 980 62. Zaph C, Scott P. Th1 Cell-Mediated Resistance to Cutaneous Infection with
981 *Leishmania major* Is Independent of P- and E-Selectins . *J Immunol.*
982 2003;171(9):4726–32.
- 983 63. Carlsen ED, Liang Y, Shelite TR, Walker DH, Melby PC, Soong L. Permissive
984 and protective roles for neutrophils in leishmaniasis. *Clin Exp Immunol.*
985 2015;182(2):109–18.
- 986 64. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of
987 infected neutrophils by dendritic cells in the skin inhibits the early anti-
988 leishmania response. *PLoS Pathog.* 2012;8(2).
- 989 65. Bogdan C, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG.
990 Fibroblasts as host cells in latent leishmaniosis. *J Exp Med.*

- 991 2000;191(12):2121–9.
- 992 66. Scorza BM, Wacker MA, Messingham K, Kim P, Klingelutz A, Fairley J, et al.
993 Differential Activation of Human Keratinocytes by Leishmania Species Causing
994 Localized or Disseminated Disease. *J Invest Dermatol* [Internet].
995 2017;137(10):2149–56. Available from:
996 <http://dx.doi.org/10.1016/j.jid.2017.05.028>
- 997 67. Rittig MG, Bogdan C. Leishmania-host-cell interaction: Complexities and
998 alternative views. *Parasitol Today*. 2000;16(7):292–7.
- 999 68. Novais FO, Carvalho LP, Passos S, Roos DS, Carvalho EM, Scott P, et al.
1000 Genomic Profiling of Human Leishmania braziliensis Lesions Identifies
1001 Transcriptional Modules Associated with Cutaneous Immunopathology. *J*
1002 *Invest Dermatol* [Internet]. 2015;135(1):94–101. Available from:
1003 <http://dx.doi.org/10.1038/jid.2014.305>
- 1004 69. Santambrogio L, Berendam SJ, Engelhard VH. The antigen processing and
1005 presentation machinery in lymphatic endothelial cells. *Frontiers in Immunology*.
1006 2019.
- 1007 70. Tamburini BA, Burchill MA, Kedl RM. Antigen capture and archiving by
1008 lymphatic endothelial cells following vaccination or viral infection. *Nat*
1009 *Commun*. 2014;
- 1010 71. Proud CG. eIF2 and the control of cell physiology. *Semin Cell Dev Biol*. 2005;
- 1011 72. Jennings MD, Pavitt GD. EIF5 has GDI activity necessary for translational
1012 control by eIF2 phosphorylation. *Nature*. 2010;
- 1013 73. Liu Y, Wang M, Cheng A, Yang Q, Wu Y, Jia R, et al. The role of host eIF2 α in
1014 viral infection. *Virology Journal*. 2020.
- 1015 74. Jaramillo M, Gomez MA, Larsson O, Shio MT, Topisirovic I, Contreras I, et al.
1016 Leishmania repression of host translation through mTOR cleavage is required
1017 for parasite survival and infection. *Cell Host Microbe*. 2011;9(4):331–41.
- 1018 75. Mahnke A, Meier RJ, Schatz V, Hofmann J, Castiglione K, Schleicher U, et al.
1019 Hypoxia in leishmania major skin lesions impairs the NO-dependent

- 1020 leishmanicidal activity of macrophages. *J Invest Dermatol.* 2014;134(9):2339–
1021 46.
- 1022 76. Schatz V, Strüssmann Y, Mahnke A, Schley G, Waldner M, Ritter U, et al.
1023 Myeloid Cell–Derived HIF-1 α Promotes Control of *Leishmania major* . *J*
1024 *Immunol.* 2016;197(10):4034–41.
- 1025 77. Weinkopff T, Roys H, Bowlin A, Scott P. *Leishmania* infection induces
1026 macrophage vascular endothelial growth factor A production in an ARNT/HIF-
1027 dependent manner. *Infect Immun.* 2019;
- 1028 78. Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for
1029 quantifying *Leishmania major* in tissues of infected mice. *Parasite Immunol.*
1030 1985;
- 1031 79. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: Summarize analysis
1032 results for multiple tools and samples in a single report. *Bioinformatics.*
1033 2016;32(19):3047–8.
- 1034 80. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
1035 Ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15–21.
- 1036 81. Anders S, Pyl PT, Huber W. HTSeq-A Python framework to work with high-
1037 throughput sequencing data. *Bioinformatics.* 2015;31(2):166–9.
- 1038 82. Robinson MD, Oshlack A. A scaling normalization method for differential
1039 expression analysis of RNA-seq data. *Genome Biol.* **11**, 1–9 (2010)
- 1040 83. Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS, et al. Why weight?
1041 Modelling sample and observational level variability improves power in RNA-
1042 seq analyses. *Nucleic Acids Res.* 2015;43(15).
- 1043 84. Benjamini, Y&Hochberg, Y. Controlling the false discovery rate: a practical and
1044 powerful approach to multiple testing. *Journal of the Royal Statistical Society*
1045 *Series B*, **57**, 289–300 (1995).
- 1046 85. Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al.
1047 Massively parallel digital transcriptional profiling of single cells. *Nat Commun*
1048 [Internet]. 2017;8:1–12. Available from:

- 1049 <http://dx.doi.org/10.1038/ncomms14049>
- 1050 86. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell
1051 transcriptomic data across different conditions, technologies, and species. *Nat*
1052 *Biotechnol.* 2018;36(5):411–20.
- 1053 87. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al.
1054 Comprehensive Integration of Single-Cell Data. *Cell.* 2019;177(7):1888-
1055 1902.e21.
- 1056 88. Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M.,
1057 Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M. Highly Parallel
1058 Genome-wide expression Profiling of Individual Cells Using Nanoliter Droplets.
1059 *Cell.* 161, 1202-1214 (2017).
- 1060 89. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and
1061 Projection for Dimension Reduction. 2018; Available from:
1062 <http://arxiv.org/abs/1802.03426>
- 1063 90. Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. MAST: A
1064 flexible statistical framework for assessing transcriptional changes and
1065 characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol*
1066 [Internet]. 2015;16(1):1–13. Available from: [http://dx.doi.org/10.1186/s13059-](http://dx.doi.org/10.1186/s13059-015-0844-5)
1067 [015-0844-5](http://dx.doi.org/10.1186/s13059-015-0844-5)
- 1068
- 1069
- 1070

1071 **Figure Legends**

1072 **Figure 1. *Leishmania* infection is associated with differential regulation of host**
1073 **immune response pathways in vivo. (A)** C57BL/6 mice were infected with 2×10^6 *L.*
1074 *major* metacyclic promastigote parasites intradermally in the ear and lesion
1075 development was monitored over time. Data are pooled from 4 experiments (n=30)
1076 and shown as +SEM. **(B)** At 4 week post-infection, parasite numbers in the ear were
1077 quantified. Data are pooled from 2 experiments (n=20) and shown as +SEM. **(C)** Multi-
1078 Dimensional Scaling (MDS) plot showing the gene expression profile between naive
1079 and *L. major*-infected ears. **(D)** Volcano plot of all DEGs in naive and infected ears.
1080 Red dots represent upregulated DEGs with $\log_2FC > 1$ and p-value < 0.05 . Blue
1081 represents down-regulated DEGs with $\log_2FC < -1$ and p-value < 0.05 . Only annotated
1082 genes are shown in plot. FC, fold-change. **(E-F)** Bulk RNA-Seq analysis indicates
1083 DEGs that are highly correlated with signaling pathways. KEGG enrichment analysis
1084 of top 20 upregulated (E), and top 20 downregulated (F) pathways enriched among
1085 the DEGs between naive and *L. major*-infected ears (pathways selected by significant
1086 and $FC > 1.5$, list includes rank, significance and adjusted average).

1087 **Figure 2: Heat map analysis of host transcriptional responses to *L. major***
1088 **infection in vivo.** Heat maps of DEGs in infected ears compared to naive controls.
1089 The DEGs involved in the host immune response pathways by KEGG enrichment
1090 analysis whether upregulated **(A, B, and C)** or downregulated **(D)** in the infected ears
1091 presented as heat maps. Hierarchical clustering of the expression profile was grouped
1092 according to functional categories. Heat maps indicate the FC of gene expression in
1093 *L. major*-infected ears > 2 -fold (red) or < 2 -fold (blue).

1094 **Figure 3. scRNA-Seq reveals cellular heterogeneity including distinct resident**
1095 **and recruited cell types in the skin following *L. major* infection. (A)** C57BL/6 mice
1096 were infected or not with *L. major* parasites in the ear, and ears were digested to
1097 isolate RNA for scRNA-Seq analysis. Schematic of cell isolation, cell processing,
1098 capture by droplet-based device. **(B)** Uniform Manifold Approximation and Projection
1099 (UMAP) plot revealed cellular heterogeneity with 35 distinct clusters of cells identified
1100 and color-coded (both naive and infected groups combined). Seurat's FindClusters
1101 function was used to identify each cell cluster and cell type designation is located to
1102 the right.

1103 **Figure 4: Cell type identification and cluster-specific gene expression. (A)**
1104 Relative expression of 35 different cell type cluster-specific genes shown as dot plots
1105 with two genes per cluster. Dot size indicates the percentage of cells expressing each
1106 gene, the dot color indicates the expression level, and ordering is performed from low
1107 to high expressing cells. **(B)** Feature plots of expression distribution for selected
1108 cluster-specific genes used to define the cell types. Expression levels for each marker
1109 is color-coded and overlaid onto UMAP plot. Cells with the highest expression level
1110 are colored black.

1111 **Figure 5: Presence of *L. major* transcripts in multiple cell types. (A)** Differential
1112 expression of *L. major* parasite transcripts in 35 different cell types. Number of cells
1113 containing parasite transcripts was shown in violin plots. **(B)** Table summarizes the
1114 percentages of individual cell that contain *L. major* transcripts.

1115 **Figure 6: scRNA-Seq analysis reveals an enhanced immune cell recruitment to**
1116 **the inflamed tissue during *L. major* infection. (A)** scRNA-Seq UMAP plots of naive
1117 and infected ears showing resident and recruited cell populations/clusters. **(B, D, F)**
1118 Representative flow cytometry plots showing the percentage of CD64⁺ macrophages


1119 (B), Ly6C⁺ inflammatory monocytes (D), and Ly6G⁺ neutrophils (F) of naive and
1120 infected ears at 4 week p.i. Cells were gated on total, live, singlets, CD45⁺ CD11b⁺
1121 cells. **(C, E, G)** Cell numbers of CD64⁺ macrophages (C), inflammatory monocytes
1122 (E), neutrophils (G) from naive and infected ears. **(H-J)** ECs were gated on total, live,
1123 singlets, CD31⁺ cells. Dermal BECs and LECs were separated by podoplanin
1124 expression during FACS analysis. (H) Representative flow cytometry dot plots
1125 showing the percentages of BECs and LECs from naive and infected ears 4 week p.i.
1126 Corresponding cell numbers of BECs (I) and LECs (J) from naive and infected ears.
1127 Data are representative of at least two independent experiments involving 10-17 mice.
1128 Data are presented as mean \pm SEM. ** $p < 0.005$, *** $p < 0.0005$, **** $p < 0.0001$,
1129 unpaired *t*-test.

1130 **Figure 7: Differentially expressed genes in selected immune cell types during *L.***
1131 ***major* infection.** Volcano plot showing the DEGs in macrophages (A), resident
1132 macrophages (B), inflammatory monocyte (C), neutrophils (D), BECs (E), and LECs
1133 (F). Colored dots indicate genes at least 2 (natural log ~0.693) fold increased (red) or
1134 decreased (blue) in infected cells relative to naive cells with an adjusted p-value <
1135 0.05.

1136 **Figure 8: Signaling pathways and molecular networks within individual cell**
1137 **types predicted during *L. major* infection by Ingenuity Pathway Analysis. (A-B)**
1138 Top 5 differentially regulated canonical pathways and their individual heat maps in
1139 macrophages following *L. major* infection. **(C-D)** Top 5 differentially regulated
1140 canonical pathways and their individual heat maps in BECs. **(E-F)** Top 5 differentially
1141 regulated canonical pathways and their individual heat maps in LECs. The color
1142 intensity represents the degree of expression. A red-green color scale was used to

1143 reflect the standardized gene expression with red representing high expression and
1144 green representing low expression. Cut-off values are adjusted p-value < 0.05.
1145

Fig. 1




1146


1147

Fig. 2


A. Antigen processing and presentation




B. Chemokine signaling pathway



C. Cell adhesion molecules (CAMs)




D. Ribosome



1148

1149

Fig. 3




1150


1151

Fig. 4

A



B




1152

1153

1154

Fig. 5

A




B

No	Cell type	% of cells contain LM transcripts
1	Basophils	1.428571429
2	BEC	0.952380952
3	Chondrocytes	0.753768844
4	Cytotoxic T cells	1.047120419
5	Dendritic Cells 1	2.716049383
6	Dendritic Cells 2	2.702702703
7	Dermal Dendritic Cells	1.515151515
8	Fibroblast 1	0.242424242
9	Fibroblast 2	0.934579439
10	Helper T Cells	1.675977654
11	Keratinocytes 1	0.705218618
12	Keratinocytes 2	1.455026455
13	Macrophage	9.99329425
14	Myoblast	5.555555556
15	Neutrophils	2.107279693
16	Outer Bulge Cells	1.005025126
17	Proliferating Keratinocytes	1.886732453
18	Resident Macrophage	4.034532133
19	Tregs	1.5525
20	gd-T cells	1.538461538

1155

1156


Fig. 6



1157

1158


Fig. 7



1159

1160

Fig. 8



1161

1162

1163

1164 **Supporting Information**

1165 **S1 Fig. Heat map analysis showing transcriptional responses from other**
1166 **immune-related pathways during *L. major* infection in vivo.** The DEGs involved in
1167 the other host immune response pathways by KEGG enrichment analysis (A, B, C and
1168 D) in the infected ears compared to naïve mice presented as heat maps. Hierarchical
1169 clustering of the expression profile was grouped according to functional categories.
1170 Heat maps indicate the FC in *L. major* infected ear gene expression >2-fold (red) or
1171 <2-fold (blue).

1172 **S2 Fig. Differentially expressed genes in selected immune cell types during *L.***
1173 ***major* infection.** Heat map showing the three highly expressed genes for at least 14
1174 immune cell clusters that were selected along with BECs and LECs. Each column
1175 represents a single cell and each row represents an individual gene. Three marker
1176 genes per cluster was color-coded and shown on the left. Yellow indicates maximum
1177 gene expression and purple indicates no expression in scaled log-normalized unique
1178 molecular identifier counts.

1179 **S3 Fig. Differentially expressed genes in DCs during *L. major* infection.** Volcano
1180 plot showing the DEGs in dendritic cells (DC1 and DC2) and list includes the top DEGs
1181 enriched in DCs following *L. major* infection. Colored dots indicate genes at least 2
1182 (natural log ~ 0.693) fold increased (red) or decreased (blue) in infected cells relative
1183 to naïve cells with an adjusted p-value < 0.05.

1184 **S4 Fig. Differentially expressed genes in CD4⁺ and CD8⁺ T cells during *L. major***
1185 **infection.** Volcano plot showing the DEGs in CD4⁺ and CD8⁺ T cells and list includes
1186 the top DEGs enriched in CD4⁺ and CD8⁺ T cells following *L. major* infection. Colored
1187 dots indicate genes at least 2 (natural log ~ 0.693) fold increased (red) or decreased
1188 (blue) in infected cells relative to naïve cells with an adjusted p-value < 0.05.

1189 **S5 Fig: IPA predicted the role of mTOR signaling in other immune cell types during *L.***
1190 ***major* infection by. (A-C)** Differentially regulated canonical pathways in DCs (A),
1191 inflammatory monocytes (B), CD4⁺ T cells following *L. major* infection.


1192 **S1 Table.** List of top 20 KEGG disease pathways enriched for differentially expressed genes
1193 (DEGs).

1194


1195

Fig. S1


A. Cytokine-cytokine receptor interaction




B. Phagosome



C. Toll-like receptor signaling pathway




D. Leukocyte trans-endothelial migration



1196


1197

Fig. S2



1198


Fig. S3. List of top 10 DEGs enriched in DC1 and DC2 clusters between infected vs naïve controls



1199


Figure

Fig. S4. List of top 10 DEGs enriched in CD4⁺ and CD8⁺T cell clusters between infected vs naïve controls



1200

Fig. S5. IPA analysis revealed the role of mTOR signaling pathway in other cell types such as dendritic cells, inflammatory monocytes, CD4⁺ T cell following *L. major* infection.



1201
 1202
 1203
 1204
 1205
 1206
 1207
 1208

1209 **S1 Table.** List of top 20 KEGG disease pathways enriched for differentially expressed genes
 1210 (DEGs).

KEGG disease pathway	Adj. p value	Avg. log-fold. change	direction
Staphylococcus aureus infection	1.34E-08	6.60312904	Up
Autoimmune thyroid disease	3.79E-08	6.020025599	Up
Graft-versus-host disease	2.19E-07	5.439582695	Up
Allograft rejection	2.76E-07	5.439582695	Up
Primary immunodeficiency	7.92E-07	8.419604409	Up
Type I diabetes mellitus	4.25E-06	5.439582695	Up
Osteoclast differentiation	3.31E-05	8.133401516	Up
Leishmaniasis	3.31E-05	6.701497553	Up
Systemic lupus erythematosus	0.00016	5.606193223	Up
Rheumatoid arthritis	0.00047	6.580971428	Up
Viral myocarditis	0.001	6.082823244	Up
Tuberculosis	0.0023	6.136724912	Up
Asthma	0.0023	2.73570696	Up
Inflammatory bowel disease (IBD)	0.0034	5.688039923	Up
Prion diseases	0.00458	-0.874425121	Down
Herpes simplex infection	0.00472	6.19895637	Up
Measles	0.00511	7.879610143	Up
Salivary secretion	0.00703	6.634176923	Up
Pertussis	0.00703	5.299789946	Up
Toxoplasmosis	0.00703	6.89131138	Up

1211